Ipca Laboratories Ltd (IPCALAB) — concall transcript | 30 June 2026

30 June 2026 · BSE 🟡 Notable Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Ipca Laboratories reported Q1 FY27 revenue growth of 13% in India's formulation segment to INR1,082 crores and 34% export growth to INR603 crores, with consolidated EBITDA margin expanding to 22.88% YoY.

🔄 What Changed

Consolidated EBITDA margin improved to 22.88% from 18.39% YoY, and FY27 EBITDA margin guidance was revised upward to 23%.

🔮 What's Next

FY27 EBITDA margin guidance revised to 23%, with FY28 revenue growth guidance of 14%-16% and margin expansion target of 22%-23%.

💡 Investor Takeaway

Shareholders should note improved profitability and biosimilars pipeline progress, though near-term growth faces material cost inflation pressures.

Ipca Laboratories reported strong Q1 FY27 growth with 13% revenue increase in India's formulation segment to INR1,082 crores and 34% export growth to INR603 crores, driving consolidated EBITDA margin expansion to 22.88% from 18.39% YoY. Management cited robust chronic segment performance and biosimilars pipeline progress, while revising FY27 EBITDA margin guidance to 23% and targeting 14%-16% revenue growth for FY28. Strategic investments in biotech and capacity expansion underscore long-term growth ambitions amid favorable regulatory and market tailwinds.

📄 View Original Announcement (PDF)

📊 Stock Analysis — IPCALAB ✨ Ask AI About This

About Ipca Laboratories Ltd (IPCALAB)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹48,712.48 CrP/E: 36.1ROE: 16.2%ROCE: 21.5%Div Yield: 0.31%

View full IPCALAB stock details →

📡 Get AI alerts when IPCALAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track IPCALAB — Free

💡 Ask AI about this filing

Ask AI Free →

📊 More IPCALAB filings

Announcement — 22 September 2026Ipca Laboratories Ltd announced that its insider trading window will close on October 1, 2026, remai...
🔴 Financial Results — 17 August 2026IPCA Laboratories reported strong Q1 FY27 growth with domestic formulation revenue up 13% to INR1,08...
🟡 Board Meeting — 13 August 2026IPCA Laboratories held its 76th Annual General Meeting on August 13, 2026 via video conference, adop...
🟡 Board Meeting — 13 August 2026The Board approved unaudited Q1 FY27 results showing consolidated revenue of **₹2,308.85 crores** (u...
Announcement — 6 August 2026IPCA Laboratories announced a conference call on August 14, 2026 at 15:30 IST to discuss Q1FY27 earn...

See all IPCALAB filings →

🔥 Also filed on 30 June 2026

AMBERAmber Enterprises India LimitedAnnouncement CGPOWERCG Power and Industrial Solutions LimitedAnnual Report ZEEMEDIAZee Media Corporation LimitedCorporate Action ZENSARTECHZensar Technologies LimitedCorporate Action ANTHEMAnthem Biosciences LimitedAnnual Report CHENNPETROChennai Petroleum Corporation LimitedAnnouncement

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when IPCALAB files new disclosures

Track IPCALAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.